Risk assessment of obstructive sleep apnea syndrome in pediatric patients with vitamin D deficiency
A questionnaire-based study
Gamze Ozgurhan, MDb,∗ Aysel Vehapoglu, MD,b Oznur Vermezoglu, MDa, Rabia Nur Temiz, MD,a
Asuman Guney, MDb, Bulent Hacihamdioglu, MDa

Abstract
The aim of the following study is to evaluate the risk of obstructive sleep apnea syndrome (OSAS) in subjects with vitamin D deficiency.

Prospective and comparative study.

We enrolled 240 subjects into the study. The participants were divided into 2 groups based on 25-hydroxyvitamin D (25(OH)D) levels: low level of 25(OH)D (<20ng/mL) group (n = 120) and control (>20ng/mL) group (n = 120). Subjects were classified as being at a high or low risk of developing OSAS by using the Berlin Questionnaire. Risk of developing OSAS, gender, age, and body mass index (BMI) z-score were assessed by comparing the low level of 25(OH)D group and control group.

No statistically significant difference was observed between the low level of 25(OH)D group and control group in terms of gender, age, and BMI z-score distributions; P = 0.323, P = 0.387, and P = 0.093, respectively. There were 24 subjects with high risk of developing OSAS in 2 groups (17 subjects in the low level of 25(OH)D group and 7 subjects in the control group). In the low level of 25(OH)D group, the risk of developing OSAS was found to be significantly higher than the control group (P = 0.030). BMI z-score was found significantly higher in high-risk groups than low-risk groups (P = 0.034 for low-level 25(OH)D group and P = 0.023 for control group).

The findings revealed that low level of 25(OH)D increases the risk of developing OSAS.

Abbreviations: 25(OH)D = 25-hydroxyvitamin D, Alk Phos = alkaline phosphatase, BMI = body mass index, BQ = Berlin Questionnaire, Ca = Calcium, OSAS = obstructive sleep apnea syndrome, PSG = polysomnography, SPSS = Statistical Package for Social Sciences, VDD = vitamin D deficiency.

Keywords: 25-hydroxyvitamin D, body mass index, sleep apnea, vitamin D deficiency, z-score

1. Introduction
Obstructive sleep apnea syndrome (OSAS) is a common disorder in childhood affecting up to 3% to 4% of all children. [1-3] The most important demographic risk factors for this disease are obesity, age, and male gender. [2,3] It has a wide spectrum of important clinical symptoms, including excessive daytime sleepiness, cognitive dysfunction, cardiovascular diseases, respiratory system infections, and metabolic dysfunction. [2-9]

Recently, it has become clear that vitamin D has many effects and plays an important role in a broad range of organ functions. It is also known that vitamin D deficiency (VDD) is a common worldwide condition. Therefore, it is essential to gain a deep understanding of the potential effects of VDD. VDD has been associated with similar metabolic disturbances as OSAS. [10-11] Although the nonskeletal consequences of VDD are not well understood, many evidence suggest that low levels of 25-hydroxyvitamin D (25(OH)D) have been associated with increases in the frequency and severity of metabolic dysfunction, obesity, and cardiovascular diseases, as well as increased incidence of respiratory tract infections. [12-18]

Nocturnal polysomnography (PSG) is required to diagnose, exclude OSAS, or assess its severity. PSG is the gold standard method for the diagnosis of OSAS but is not suitable for screening. The sleep questionnaire is easily applicable and predicts polysomnographic results to an extent that is useful for clinical research.

In this study, we investigate the risk of OSAS by using a sleep questionnaire in children with VDD. We hypothesize that risk of OSAS is higher in children with reduced vitamin D.

2. Materials and methods
This prospective and comparative study was performed at the Suleymaniye Maternity and Children’s Training and Research
Hospital. The study was conducted according to the principles of the Declaration of Helsinki and was approved by the local ethics committee. The subjects and their parents were informed, and they provided written informed consent.

2.1. Study groups

Subjects were divided into 2 groups according to levels of 25(OH)D, a low-level 25(OH)D group (<20 ng/mL) and a control group (>20 ng/mL). The low-level 25(OH)D group was matched for age, sex, and body mass index (BMI) z-score with the control group.

Each participant underwent a comprehensive assessment including a review of medical history, physical examination, and height and weight measurements. The study included the subjects who were healthy individuals without any chronic disease such as chronic renal failure, malabsorption, nutritional rickets, and adenotonsillar disease. There was no subject with a history of OSAS in both groups. No participant reported taking calcium (Ca) or multivitamin supplements. Furthermore, all participants needed to be 7 to 14 years old.

2.2. Laboratory

25(OH)D plasma level was assessed at UniCel DxI 800 autoanalyzer using access immunoassay system 25(OH)D (Beckman Coulter, O’Callaghan’s Mills, Ireland) kit with chemiluminescence method. Ca and phosphor levels were assessed at Cobas c 501 autoanalyzer using Ca2 and Phos2 (Roche/Hitachi, Berlin, Germany) kits with photometric method. Alkaline phosphatase (Alk Phos) plasma level was assessed at Cobas c 501 autoanalyzer using AlP2 (Roche/Hitachi) kit with calorimetric method. Normal values were 8.4 to 10.2 mg/dL for Ca, 3.1 to 5.3 mg/dL for phosphor and <300 U/L for Alk Phos.

2.3. Berlin Questionnaire

The Berlin Questionnaire (BQ) was completed during face-to-face interviews with subjects and their parents in this study. The participants were questioned primarily about their OSAS history, and the BQ was used to evaluate the risk of developing OSAS. Using the BQ, which has 3 parts, subjects were reliably classified as being at a high or low risk of developing OSAS. The criteria were snoring behavior, daytime sleepiness, and high blood pressure or obesity. Obesity was defined with BMI z-score > 2. It is calculated by dividing weight (kg) by square of height (m) and then transformed to an age- and sex-specific z-score. If 2 of these 3 conditions were present, subjects were classified as being at a high risk of developing OSAS. The questionnaires were analyzed by the same specialist (GO), and the observer was masked to control group.

2.4. Data analysis

All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 20.0 for Windows (SPSS, Chicago, IL). The 1-sample Kolmogorov–Smirnov test was used to evaluate the distribution characteristics of variables. Demographic and clinical characteristics of low 25(OH)D and control groups were compared using the Mann–Whitney U test for continuous variables and the χ2 test for categorical variables. Differences were considered statistically significant for P values less than 0.05.

3. Results

The study included 240 subjects: 120 subjects in the low-level 25(OH)D group and 120 subjects in the control group. No statistically significant difference was observed between the 2 groups in terms of gender, age, and BMI z-score distributions; P = 0.323, P = 0.387, and P = 0.093, respectively. High risk of developing OSAS was significantly higher in the low-level 25(OH)D group than in the control group (P = 0.030). The demographic and clinical characteristics of both groups are shown in Table 1.

When 2 groups were classified as being at a high or low risk of developing OSAS, there were no significant differences for gender and age between high- and low-risk groups. In high-risk groups, BMI z-score was found to be significantly higher than low-risk groups (Table 2).

4. Discussion

In this study, we assessed the risk of developing OSAS in children with VDD. Although there is no study in the literature similar to ours, there are many studies that report VDD in adult or children patients with OSAS and results of these studies are correlated with those of ours. This study has shown that the risk of developing OSAS as determined by the BQ was found to be statistically significantly higher in low-level 25(OH)D group when compared with the control group (P = 0.030). The percentage of patients at a high risk of developing OSAS was 14.16% for the low-level 25(OH)D group and 5.83% for the control group.

Table 1
The demographic and clinical characteristics of low-level 25(OH)D and control groups.

| Characteristics | Low-level 25 (OH)D group (n = 120) | Control group (n = 120) | P |
|-----------------|-----------------------------------|-------------------------|---|
| Gender (male/female) | 56/62 | 52/68 | 0.323 |
| Age, y | 10.35 (±2.25); (7–14) | 10.07 (±2.31); (7–14) | 0.387 |
| BMI (z-score) | –0.04 (±1.35); (–2.88 to 2.82) | 0.28 (±1.53); (–3.07 to 3.69) | 0.093 |
| 25(OH)D, ng/mL | 13.10 (±4.02); (7–19.83) | 27.12 (±5.63); (20.69–44.7) | 0.030 |
| Ca, mg/dL | 9.81 (±0.29); (9.18–10.18) | 9.65 (±0.30); (9.25–10.13) | 0.334 |
| Pi, mg/dL | 4.62 (±0.58); (3.29–5.28) | 4.51 (±0.51); (3.13–5.25) | 0.172 |
| Alk Phos, U/L | 226.90 (±50.89); (120–296) | 235.45 (±66.49); (86–295) | 0.552 |
| High risk of OSAS | 17 (14.16%) | 7 (5.83%) | 0.030 |

25(OH)D = 25-hydroxyvitamin D, Alk Phos = alkaline phosphatase, BMI = body mass index, Ca = calcium, OSAS = obstructive sleep apnea syndrome, Pi = inorganic phosphorus, SD = standard deviation. 

P values are from the χ2 test for categorical variables and from the Mann–Whitney U test for continuous variables.

*Statistically significant increased values (P < 0.05).
Obesity is one of the best defined risk factors for OSAS. BMI is strongly associated with OSAS prevalence.\[13\] On the other hand, there is an inverse association between BMI and 25(OH)D. In many studies, obesity has been found to be common in patients with OSAS.\[22\]–\[25\] In our study, median BMI z-score values were within normal range in low-level 25(OH)D and control groups (\(P = 0.093\)). But in the patients with high risk of developing OSAS, BMI z-score was found to be significantly higher than the patients with low risk of developing OSAS in both the low-level 25(OH)D and control groups.

Many studies show that the decline in 25(OH)D level is associated with risk of OSAS in children. Recently, functional roles of 25(OH)D have been unveiled. Vitamin D insufficiency is widely prevalent and leads to many health problems beyond bone disease, such as nonspecific pain and noninflammatory skeletal myopathy, which may disrupt sleep and directly cause daytime sleep impairment. Emerging lines of evidence suggest that low vitamin D levels increase the risk for autoimmune disease, chronic rhinitis, tonsillar hypertrophy, cardiovascular disease, metabolic syndrome, and diabetes. It was claimed that persistent inadequacy of vitamin D may also increase the risk for obstructive sleep apnea via promotion of adenotonsillar hypertrophy, airway muscle myopathy, and/or chronic rhinitis.\[12\]–\[16\],\[24\]–\[30\] In this study, we only show that OSAS may be high in children with VDD but we could not evaluate pathogenic link between the two. Also in this study, we define the VDD according to the cutoff value of bone health, but optimal vitamin D level for nonskeletal organs and tissues is not known.

Vitamin D is essential for an appropriately responsive immune system. Inadequate vitamin D clinically results in increased risk of infections and inflammation involving the upper and lower airway. This may increase the risk for OSAS. Also vitamin D contributes to sleepiness through such central signaling, and inflammatory mediators are likely to be involved. The sleep-regulating substances, tumor necrosis factor-alpha and IL-1, both exhibited inverse relationships with 25(OH)D. More information is needed regarding the link between circulating 25(OH)D and OSAS.\[15\]–\[18\] However, our study is not focused on the causal link between these conditions.

25(OH)D was inversely associated with numerous OSAS parameters as documented with PSG. This inverse correlation has been reported by Bozkurt et al.\[23\] They pointed out that those patients with more severe OSAS polysomnographic indices tended to present lower vitamin D levels. In another study, 25(OH)D was associated with OSAS according to multivariate logistic regression analysis.\[25\]

Although the BQ for OSAS risk evaluation is a widely used and reliable test, this research was restricted by some limitations. First, the evaluation of OSAS risk was done only with BQ rather than an additional confirmation with PSG. Second, this study has a relatively small sample size, and a larger study population is needed to validate these findings. Even with these limitations, this is the first study evaluating risk of OSAS in VDD cases.

In summary, low level of vitamin D is common in childhood and may be the cause of or a contributor to some disorders such as OSAS. Obstructive sleep apnea syndrome reduces quality of life by affecting central nervous system, cardiovascular system, metabolic system, and somatic growth. In this study, we have concluded that there is a correlation between low vitamin D levels and risk of OSAS. To prevent potential negative impacts of OSAS and decrease its morbidity, there is need for broader and deeper follow-up studies.

### Table 2

Characteristics of risk of developing OSAS in low-level 25(OH)D and control groups.

| Characteristics              | Low-level 25 (OH)D group (n = 120) | Control group (n = 120) |
|------------------------------|------------------------------------|-------------------------|
|                              | Low risk                          | High risk               | \(P\) | Low risk                          | High risk               | \(P\) |
| Gender (male/female)         | 53/50                             | 51/2                    | 0.640 | 50/63                             | 2/5                     | 0.127 |
| Age, \(\text{y}\)            | 10.31 (±2.07)                     | 10.52 (±3.04)           | 0.721 | 10.10                             | 9.57 (±2.63)            | 0.618 |
| (7–14)                       | (7–14)                             |                         |       | (±2.30); (7–14)                   | (7–12)                  |       |
| BMI (z-score)               | –0.26 (±1.25)                     | 1.01 (±1.33)            | 0.034 \* | 0.15 (±1.47); (7–12)              | 1.99 (±1.27); (7–12)   | 0.023 \* |
| (–2.88 to 2.82)             | (–1.34 to 2.81)                   |                         |       | (–3.07 to 3.61); (7–12)           | (0.48–3.69)             |       |

25(OH)D = 25-hydroxyvitamin D, BMI = body mass index, OSAS = obstructive sleep apnea syndrome, SD = standard deviation. \(P\) values are from the \(\chi^2\) test for categorical variables and from the Mann–Whitney \(U\) test for continuous variables.

\* Statistically significantly increased values (\(P < 0.05\)).

### References

1. Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2012;130:714–55.
2. Bhattacharjee R, Kim J, Kheirandish-Gozal L, et al. Obesity and obstructive sleep apnea syndrome in children: a tale of inflammatory cascades. Pediatr Pulmonol 2011;46:313–23.
3. Gozal D, Kheirandish-Gozal L, Bhattacharjee R, et al. C-reactive protein and obstructive sleep apnea syndrome in children. Front Biosci 2012;4:2410–22.
4. Panosssian LA, Yasscy SC. Daytime sleepiness in obesity: mechanisms beyond obstructive sleep apnea—a review. Sleep 2012;35:605–15.
5. Naismith S, Winter V, Gotsopoulos H, et al. Neurobehavioral functioning in obstructive sleep apnea: differential effects of sleep hypoxemia, sleep quality and subjective sleepiness. J Clin Exp Neuropsychol 2004;26:43–54.
6. Newman AB, Nieto FJ, Guduy U, et al. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001;154:30–9.
7. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829–36.
8. Seiccen S, Kirchner HL, Gottlieb DJ, et al. Sleep disordered breathing and impaired glucose metabolism in normal weight and overweight/obese individuals: the Sleep Heart Health Study. Diabetes Care 2008;31:1001–6.
9. Reichsmuth KJ, Austin D, Skatrud JB, et al. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005;172:1590–5.
10. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
11. Osei K. 25-OH vitamin D: is it the universal panacea for metabolic syndrome and type 2 diabetes? J Clin Endocrinol Metab 2010;95:4220–2.
12. Kelly A, Brooks LJ, Dougherty S, et al. A cross-sectional study of vitamin D and insulin resistance in children. Arch Dis Child 2011;96:477–52.
13. Pacifio L, Anania C, Osborn JF, et al. Low 25(OH)D3 levels are associated with total adiposity, metabolic syndrome, and hypertension in Caucasian children and adolescents. Eur J Endocrinol 2011;165:603–11.
Olson ML, Maalouf NM, Oden JD, et al. Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J Clin Endocrinol Metab 2012;97:279–85.

Salo A, Logomarsino JV. Relationship of vitamin D status and cardiometabolic risk factors in children and adolescents. Pediatr Endocrinol Rev 2011;9:456–62.

Reyman M, Verrijn Stuart AA, Van Summeren M, et al. Vitamin D deficiency in childhood obesity is associated with high levels of circulating inflammatory mediators, and low insulin sensitivity. Int J Obes (Lond) 2014;38:46–52.

Turer CB, Lin H, Flores G. Prevalence of vitamin D deficiency among overweight and obese US children. Pediatrics 2013;131:152–61.

Science M, Maguire JL, Russell ML, et al. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. Clin Infect Dis 2013;57:392–7.

Mete Y, Yalcin D, Berker B, et al. Obstructive sleep apnea syndrome and its association with vitamin D deficiency. J Endocrinol Invest 2013;36:681–5.

Kheirandish-Gozal L, Peris E, Guzal D. Vitamin D levels and obstructive sleep apnea in children. Sleep Med 2014;15:459–63.

Bozkurt NC, Cakal E, Sahin M, et al. The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 2012;41:5182–5.

Kerley CP, Hutchinson K, Bolger K, et al. Serum vitamin D is significantly inversely associated with disease severity in Caucasian adults with obstructive sleep apnea syndrome: a case control study. Sleep 2016;39:293–300.

Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinol Metab Clin North Am 2003;32:869–94.

Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217–39.

Erdem ES, Genc S, Motor S, et al. Investigation of serum bisphenol A, vitamin D, and parathyroid hormone levels in patients with obstructive sleep apnea syndrome. Endocrine 2014;45:311–8.

Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012;33:456–92.

Creo AL, Rosen JS, Ariza AJ, et al. Vitamin D levels, insulin resistance, and cardiovascular risks in very young obese children. J Pediatr Endocrinol Metab 2013;26:97–104.

Kayanyil S, Vieth R, Remnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010;33:1379–81.

McCarty DE, Chesson AJ Jr, Jain SK, et al. The link between vitamin D metabolism and sleep medicine. Sleep Med Rev 2014;18:311–9.

Reid D, Morton R, Salkeld L, et al. Vitamin D and tonsil disease preliminary observations. Int J Pediatr Otorhinolaryngol 2011;75:261–4.

Adams JS, Liu PT, Chun R, et al. Vitamin D in defense of the human immune response. Ann N Y Acad Sci 2007;1117:94–105.

Bellia A, Gavdic C, D’Adamo M, et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med 2011;6:33–40.

Khoo AL, Chui LY, Koenen HJ, et al. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol 2011;164:72–9.

Pinelli NR, Jaber LA, Brown MB, et al. Serum 25-hydroxyvitamin D and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care 2010;33:1373–5.